Estrogen Receptor — Hormone Binding Biomarker

An estrogen receptor (ER) is a nuclear hormone receptor and ligand-activated transcription factor. When circulating estrogen molecules bind to ER within a cell, the receptor dimerises, translocates to the nucleus, and binds to specific DNA sequences known as estrogen response elements. This molecular cascade directly stimulates the transcription of genes responsible for cell survival, proliferation, and tissue development.

In malignant cells, this normal physiological mechanism can be co-opted. Tumours that overexpress estrogen receptors depend heavily on estrogen signalling to proliferate. Pathologists routinely assess ER status on tumour specimens to classify the cancer as ER-positive (ER+) or ER-negative (ER-), a vital distinction that defines the tumour's biological subtype.

Establishing estrogen receptor status is essential for personalising cancer management. ER-positive cancers typically carry a more favourable short-to-medium-term prognosis compared to receptor-negative tumours and respond favourably to targeted endocrine therapies. Knowing the ER status prevents the unnecessary use of ineffective hormone treatments in ER-negative patients while unlocking a cornerstone group of therapies for ER-positive individuals, dramatically lowering the risk of local recurrence and distant disease spread.

Estrogen receptor status is evaluated on formal tissue biopsy or surgical resection specimens using immunohistochemistry (IHC). Pathologists apply specific antibodies to tissue slides to measure the percentage of cell nuclei that stain positive, as well as staining intensity. Under international guidelines, tumours showing at least 1% of tumour cell nuclei with positive nuclear staining are classified as ER-positive.

The estrogen receptor is most famously evaluated in breast cancer, where approximately 70 to 80 percent of newly diagnosed tumours are ER-positive. ER evaluation is also clinically relevant in endometrial (uterine) cancers, ovarian epithelial tumours, and occasionally low-grade neuroendocrine or salivary gland neoplasms.

ER-positive tumours are treated with endocrine therapies designed to deprive cells of estrogen stimulation. In premenopausal women, selective estrogen receptor modulators like tamoxifen or ovarian suppression drugs are standard. In postmenopausal women, aromatase inhibitors (such as letrozole, anastrozole, or exemestane) stop peripheral estrogen synthesis. Selective estrogen receptor degraders (SERDs) like fulvestrant or newer oral options are used if resistance develops.